Activating mutations of the epidermal growth factor receptor gene (EGFR) are a driving force
for some lung adenocarcinomas. Several randomized phase III studies have revealed that …

The availability of 3 generations of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …

Background Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …

Abstract The phosphoinositide 3-kinase (PI3K) pathway, one of the most commonly
activated signaling pathways in human cancers, plays a crucial role in the regulation of cell …

Lung cancer is the second most common cancer and the leading cause of cancer-related
deaths. Different targeted therapies and the introduction of immunotherapy have …

Background Dual blockade of both EGFR and VEGFR pathways in EGFR‐mutant NSCLC
have shown enhanced antitumor efficacy versus EGFR‐TKIs alone. Apatinib is an orally …

Background Acquired resistance development is a major challenge in the epidermal growth
factor receptor‐tyrosine kinase inhibitor (EGFR–TKI) treatment of non–small cell lung cancer …

Therefore, potentially four different therapeutic options are available in first-line therapy of
EGFR mt+ NSCLC, first, second, third generation, TKI+ antiangiogenic agent and TKI+ …

Introduction Previous studies have shown the potentials of anti-angiogenesis inhibitors in
extensive-stage small-cell lung cancer (SCLC). This single-institutional phase 1b study …

Over the last 15 years, multiple generations of EGFR tyrosine kinase inhibitors (TKIs) have
completely transformed the landscape of management of EGFR-mutated lung cancers but …